Serious safety events in rituximab-treated multiple sclerosis and related disorders.

Brandi L VollmerAsya I WallachJohn R CorboyKarolina DubovskayaEnrique Alvarez Ilya Kister

Published in: Annals of clinical and translational neurology (2020)

Rates of SSEs in patients with MS, NMOSD, and related disorders were low. Through properly assessing risk:benefit of B-cell depleting therapy in neuroinflammatory disorders and continual monitoring, clinicians may decrease the risk of serious infections.

Keyphrases

multiple sclerosis
diffuse large b cell lymphoma
white matter
mass spectrometry
palliative care
ms ms
hodgkin lymphoma
chronic lymphocytic leukemia
newly diagnosed
replacement therapy